Mechanism of drug action
According to the instructions for Piaskledin 300, the product belongs to herbal preparations. The main purpose is to regulate metabolism in cartilage tissues.
Taking capsules helps:
- relieving pain and inflammation in joints;
- inhibition of destructive processes in cartilage;
- restoration of motor activity;
- stimulating collagen production in joint tissue cells.
The medicinal effect occurs due to unsaponifiable compounds of avocado oil and soybeans, which:
- increase the volume of collagen produced in cartilage tissues, due to which their firmness and elasticity increase;
- reduce the synthesis of collagenase, an enzyme that can break down collagen;
- regulate the activity of plasminogens, thereby preventing the destruction of cartilage tissue;
- promote the synthesis of periodontal tissue and serve as a preventive measure for tooth loss.
The unsaponifiable part of the oil contains vitamins, carotenoids, minerals, acids, phytosterols and other biologically active substances. The presence of unsaponifiable lipids helps suppress the inflammatory process that accompanies the destruction of cartilage tissue when affected by arthrosis or arthritis.
Expert recommendations
Some of the best drugs for treating OA pain are NSAIDs. Unfortunately, patients who have had a myocardial infarction or heart surgery, or who have high blood pressure (very high or high risk of cardiovascular disease) should avoid using any NSAIDs. In this case, it is possible to take paracetamol, and in the presence of severe pain, after consultation with a doctor, tramadol or drugs of other groups.
For patients at low risk of developing cardiovascular and low or moderate risk of gastrointestinal complications, any NSAID may be recommended. Their choice can be determined depending on the presence of acute or chronic pain and the severity of the inflammatory process. Although all NSAIDs are considered equally effective at maximum permitted doses, their effects on the rate and duration of pain relief vary. The most powerful analgesic potential is diclofenac potassium and ketoprofen.
If patients with OA have even moderate risks of developing complications from the cardiovascular system or gastrointestinal pathology, taking NSAIDs is unsafe, and the choice of drug should be agreed upon and prescribed by your attending physician!
According to evidence-based medicine and the opinion of international experts, complex therapy for OA should include agents that affect inflammation and metabolic processes in cartilage tissue and chondrocytes (glucosamine sulfate or glucosamine hydrochloride, chondroitin sulfate, a combination of chondroitin sulfate and glucosamine hydrochloride, unsaponifiable compounds of avocado and soy, diacerein and hyaluronic acid). Summarizing the findings of most RCTs, from a practical point of view, these drugs have a reliable analgesic and anti-inflammatory effect; increase functional activity; reduce morning stiffness and starting pain.
A number of studies have shown the effect of unsaponifiable compounds from avocado and soy (Piascledine 300) in reducing the levels of pro-inflammatory cytokines. In a domestic study, it was shown that unsaponifiable compounds of avocado and soy lead to a decrease in markers of systemic inflammation (TNF-α, IL-1β, R-IL2, CRP) by an average of 30% over 3 months of therapy, and also demonstrated a leveling of clinical symptoms of OA , primarily pain, as well as a decrease in the intensity of endothelial dysfunction due to the addition of the drug to the main therapy of cardiovascular diseases. It has been shown to reduce the need for NSAIDs and maintain the functional activity of the affected joints.
Do not cancel therapy with these drugs if they were previously prescribed to you by your doctor!
Local therapy for OA includes intra- or periarticular administration of glucocorticoids, intra-articular administration of hyaluronic acid preparations, as well as local application of NSAID-based ointments (creams, gels) to the joint area.
However, intra-articular glucocorticoids should be avoided during the COVID-19 pandemic. In addition to the risk of being in a health care setting, there is also a hypothetical risk that exposure to an intra-articular glucocorticoid may weaken the immune response of patients with OA.
Local application of creams and gels with NSAIDs (arthrosilene, ketonal, fastum-gel, voltaren, etc.) will help you reduce pain and improve joint function.
According to modern data, obesity is a risk factor for OA and many other diseases associated with metabolic disorders, and dysfunction and disability, as a rule, accompanying OA, in turn lead to an increase in body mass index and induce the development of cardiovascular diseases and diabetes.
Now is the time to start reducing your weight by reducing calories and doing exercise!
Chew your food thoroughly (the feeling of hunger and satiety occurs much faster, you can limit the amount of food consumed). Reduce portions to fit your fist! Distribute meals evenly over 4-5 times a day, the last meal should not be later than 3 hours before bedtime.
Benefits of Piascledine for athletes
The joints of athletes and people whose work involves heavy physical labor experience increased stress. In addition, playing sports is often accompanied by injuries, inflammation and pain.
You can take Piaskledin 300 to prevent sports injuries to joints and cartilage, to quickly relieve the inflammatory process to prevent it from becoming chronic. For sprains and injuries to the knee and hip joints, the capsules will help you recover faster.
To reduce the severity of inflammation, as well as the natural restoration of the joint and cartilage tissue, Piascledine should be taken in the postoperative period.
Pharmacological properties
The mechanism of action of unsaponifiable compounds from avocado and soybean oils was assessed in in vitro and in vivo studies in a group of patients with osteoarthritis, the results of which demonstrated the following main pharmacological properties:
- enhance collagen synthesis by articular chondrocytes and reduce the synthesis of IL-1 (interleukins-1) by chondrocytes;
- increase the expression of PAI-1 (plasminogen activator inhibitor, a fraction that inhibits plasminogen activator, which causes joint damage in osteoarthritis);
- increase the expression of transforming growth factor β (TGF-β) in chondrocytes, which was later recognized to exhibit anabolic properties relative to cartilage tissue.
All of the above properties of unsaponifiable compounds of avocado and soybean oils suggest that the drug Piaskledin 300 stimulates TGF-β, which leads to the restoration of the extracellular matrix component in articular cartilage tissue.
When assessing the effect of Piascledine 300, namely by the values of 3 selected indices (gum inflammation, gum bleeding, bleeding on probing), a decrease in the severity of gum inflammation was noted.
There was a significant decrease in the number of exacerbations of gum inflammation when patients were treated with Piascledine 300.
Reviews
Experts speak positively about the drug: the capsules are highly effective and have a natural composition. Easy to use, as one piece per day is enough. The drug helps reduce pain in chronic diseases of the spine and lower back pain. The disadvantages are the high cost of the course of treatment and the need for long-term therapy, since the drug has a cumulative effect.
Patients note a decrease in pain, swelling of the joints, the disappearance of crunching, the return of the ability to move without pain, and the disappearance of the dependence of the condition on weather changes.
Side effects
Criteria for assessing the frequency of adverse reactions: very often (≥1/10), often (≥1/100, 1/10); uncommon (≥1/1000, 1/100), rare (≥1/10,000, 1/1000), very rare (1/10,000), frequency unknown (cannot be determined from available data).
From the digestive system: very rarely - belching with a fatty taste, which can be avoided by taking the capsule with meals, diarrhea and epigastric pain.
From the liver and biliary tract: very rarely - increased transaminases, alkaline phosphatase, bilirubin and gammaglutamyl transpeptidase.
From the immune system: very rarely - hypersensitivity reactions.
If side effects occur or symptoms worsen, you should consult a doctor.
About the manufacturer
The French independent pharmaceutical and dermocosmetic laboratory Expanscience achieved a turnover of 271.2 million euros in 2021, 61.9% of which were international deliveries; The company employs 1,105 people.
Over 60 years of development, the company has developed an international reputation for seriousness, innovation and expertise in the treatment of osteoarthritis and skin diseases. Its products, which include two leading brands - Piascledine 300 and Mustela - are represented in more than 120 countries (16 subsidiaries and 102 distribution countries). The Expanscience laboratory also develops and markets ingredients of natural origin for the cosmetics industry in France and abroad.
Keeping people healthy, be it their mobility or their skin, has been at the heart of the group's growth strategy from the very beginning.
In its commitment to supporting healthcare professionals in their roles of prevention, counseling and information, Expanscience has undertaken numerous activities in the areas of education, pedagogy and patient and consumer experience.
The entire chain of product creation, from research to distribution, is controlled by the company.
The laboratory's pioneering research into cartilage and the protective functions of skin has led to 933 patent applications worldwide.
Manufactured with respect for people and the environment, Piascledine® 300 is produced in Épernon, France, in an ISO 14001 certified site. This quality guarantee and the “Made in France” mark represent key elements of its international influence.
In 2004, Expanscience Laboratory launched a social responsibility policy. This commitment is reflected, inter alia, in the responsible sourcing of plant materials as well as in more environmentally friendly product development.
Expanscience Laboratory is an AFAQ 26000 Exemplary (AFNOR Certified Social Responsibility Assessment Methods, Meeting ISO 26000 Organizational Social Responsibility Standard Criteria) and the first pharmaceutical and dermocosmetic laboratory in the world to achieve B Corp certification, an international designation awarded to companies making a positive impact. on society and the environment.
Expanscience laboratory in numbers
Date of creation: 1950
Turnover 2021: 271.2 million euros
International share: 61.9%
Almost 120 countries (16 subsidiaries and 102 distribution countries)
1105 employees
933 patent applications
67 million products produced in 2021
Activities: Dermocosmetology, Dermatology, Rheumatology, Cosmetics
Find out more: www.expanscience.com
Approach to corporate social responsibility
Expanscience Laboratory
Initiated over 10 years ago, our approach to corporate social responsibility (CSR) mobilizes the expertise and innovation potential of our teams - in collaboration with our partners - to care for our patients and their environment.
This is a voluntary initiative carried out at the highest level.
Expanscience is the first French pharmaceutical and dermocosmetic laboratory to achieve B Corp certification and achieve AFAQ 26000 Exemplary level.
Introducing innovations for prevention and treatment
Full offer cycle: from medicine to patient support
Expanscience is a member of UEBT for the conservation of biodiversity and ethical trading.
Note!
Description of the drug Piaskledin 300 caps. No. 15 on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.
special instructions
The drug contains soybean oil, so if you are allergic to soy or peanut products, you should not use the drug.
Piaskledine 300 belongs to a new class of drugs SYSADOA (symptomatic slow-acting agents for the treatment of osteoarthritis), the main property of which is their delayed action. For this reason, at the beginning of treatment with Piascledine 300, the administration of NSAIDs and/or analgesics can be recommended, the dose of which should be gradually reduced in accordance with the increase in the effectiveness of Piascledine 300.
Use during pregnancy and lactation. No studies have been conducted on the use of the drug in pregnant women, so the use of the drug during pregnancy is not recommended.
There is no data on the use of the drug during breastfeeding, so you should refrain from using the drug during this period.
Children. The drug should not be used in children (under 18 years of age) due to the lack of studies on the effectiveness and safety of this drug in patients of this age category.
The ability to influence reaction speed when driving vehicles or working with other mechanisms. Piascledine 300 has no known effect on the ability to drive vehicles or operate machinery.